Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Intellia Therapeutics Inc. (NTLA)

17.12   -0.33 (-1.89%) 08-20 10:39
Open: 17.7 Pre. Close: 17.45
High: 17.43 Low: 17.07
Volume: 57,034 Market Cap: 831M

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 17.797 - 17.865 17.865 - 17.944
Low: 17.085 - 17.158 17.158 - 17.242
Close: 17.314 - 17.431 17.431 - 17.566

Technical analysis

as of: 2019-08-20 10:02:42 AM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 20.95     One year: 22.19
Support: Support1: 16.22    Support2: 13.50
Resistance: Resistance1: 17.94    Resistance2: 19.00
Pivot: 17.44
Moving Average: MA(5): 17.22     MA(20): 17.63
MA(100): 16.26     MA(250): 17.94
MACD: MACD(12,26): 0.14     Signal(9): 0.26
Stochastic oscillator: %K(14,3): 32.06     %D(3): 26.08
RSI: RSI(14): 51.41
52-week: High: 32.95  Low: 11.03  Change(%): -40.8
Average Vol(K): 3-Month: 57601  10-Days: 41215

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
NTLA has closed above bottom band by 41.2%. Bollinger Bands are 43.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to NTLA's normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Thu, 01 Aug 2019 19:01:42 Z
Intellia Therapeutics, Inc. (NTLA) Q2 2019 Earnings Call Transcript

Thu, 01 Aug 2019 15:07:27 Z
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates

Wed, 31 Jul 2019 17:59:10 Z
Is Intellia Therapeutics a Buy?

Tue, 23 Jul 2019 22:09:51 Z
CRISPR Could Change Medicine, But Not in the Way Wall Street Expects

Wed, 10 Jul 2019 14:08:59 Z
Here's Why CRISPR Gene Editing Stocks Rose as Much as 32.4% in June

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 45.22
Shares Float (M) 38.30
% Held by Insiders 22.51
% Held by Institutions 71.58
Shares Short (K) 8210
Shares Short P. Month (K)

Stock Financials

EPS -2.000
EPS Est. Current Year -1.780
EPS Est. Next Year -2.060
EPS Est. Next Quarter -0.460
Forward EPS -2.660
Book Value (p.s.) 5.800
PEG Ratio -0.24
Profit Margin -242.65
Operating Margin -260.90
Return on Assets (ttm) -17.4
Return on Equity (ttm) -32.1
Qtrly Rev. Growth 44.8
Gross Profit (p.s.) -1.298
Sales Per Share
EBITDA (p.s.) -2.015
Qtrly Earnings Growth
Operating Cash Flow (M) -70.12
Levered Free Cash Flow (M) -59.84

Stock Valuations

P/E -8.66
P/E Growth Ratio -0.01
P/BV 2.99
P/S 943627008.00
P/CF -11.17

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.